| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
SARS-CoV-2 RNA, Influenza A/B, and RSV RNA, Qualitative NAAT
Test Code39816
CPT Codes
CPT is dependent on the method/manufacturer kit that is used. (Cepheid 0241U or Hologic 87637) <br><strong>To meet regulatory reporting requirements for COVID-19 testing, the patient's address, phone number and other demographic details are required for this order.</strong>
Preferred Specimen
One (1) nasopharyngeal swab collected in VCM or UTM.
Please read detailed instructions below related to collection and transport.
Minimum Volume
1 swab in transport media • 1 swab in transport nasopharyngeal or nasal swab • 0.6 mL nasal wash aspirate in 3 mL viral transport
Other Acceptable Specimens
Nasal swab collected in VCM, UTM, or equivalent media
Instructions
Please read detailed instructions below related to collection and transport.
Specimens should be transported refrigerated and are stable for up to 7 days. Cold packs/pouches should be used if placing specimens in a lockbox for courier pick-up. Each COVID-19 specimen transport vial that is submitted should be accompanied by its own separate requisition and transported in its own sealed bag.
Specimens should be transported refrigerated and are stable for up to 7 days. Cold packs/pouches should be used if placing specimens in a lockbox for courier pick-up. Each COVID-19 specimen transport vial that is submitted should be accompanied by its own separate requisition and transported in its own sealed bag.
Transport Container
VCM, UTM
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 24 hours
Refrigerated: 7 days
Frozen:
Nasopharyngeal or nasal swab collected in VCM, UTM, equivalent media: 3 months at -70° C
Refrigerated: 7 days
Frozen:
Nasopharyngeal or nasal swab collected in VCM, UTM, equivalent media: 3 months at -70° C
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Calcium alginate swabs • Cotton swabs in wooden shaft • Amies liquid or gel transport for bacterial cultures • Tubes with clot activator • Glass tubes • Snap-cap tubes • 3D printed swabs • Media with guanidine isothiocyanate (GITC) due to safety concerns • Specimen at room temperature for >24 hours • Throat and lower respiratory samples • Transport tube with the swab inverted
Methodology
Nucleic Acid Amplification Test including Reverse Transcription Polymerase Chain Reaction (RT-PCR) and/or Transcription Mediated Amplification (TMA)
FDA Status
The test for detection of SARS-CoV-2 has been authorized by the FDA under and Emergency Use Authorization (EUA) for use by authorized laboratories.
Setup Schedule
Mon, Wed, Fri
Report Available
2 days
Reference Range
| Influenza A RNA | Not detected |
| Influenza B RNA | Not detected |
| RSV RNA | Not detected |
| SARS CoV2 RNA | Not detected |
Clinical Significance
SARS-CoV-2 RNA, Influenza A/B, and RSV RNA, Qualitative NAAT is a multitarget molecular test that aids in simultaneous qualitative detection and differentiation of SARS-CoV-2 (COVID-19), influenza A, influenza B, and respiratory syncytial virus (RSV) viral RNA. This test is intended to be performed on respiratory specimens collected from individuals suspected of respiratory viral infection consistent with COVID-19 or influenza or RSV by their healthcare provider. Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2, influenza, and RSV can be similar.
Click here to see turnaround time
Click here to see turnaround time
Performing Laboratory
| Quest Diagnostics-Pittsburgh Lab |
| 875 Greentree Road |
| Pittsburgh, PA 15220-3508 |
